Biosimilars: Expanding Access to Life-Changing Biologic Therapies
Introduction to Biosimilars
Biosimilars are biologic medications that are developed to be similar to an already approved biologic drug, known as the reference product. Biosimilars undergo rigorous testing to show they are highly similar to the reference product in terms of safety and efficacy. Unlike generic drugs which are exact copies of their reference products, biosimilars are not identical but rather highly similar due to the complex nature of biologics which are produced in living systems. The small differences that can exist do not affect safety or efficacy.
Regulatory Approval Process for Biosimilars
For a biosimilar to be approved, it must go through a rigorous approval process conducted by expert regulatory agencies. Extensive analytical, animal, and clinical testing is required to demonstrate biosimilarity to the reference product. Analytical studies involve detailed physiochemical and biological characterization of the Biosimilars and reference product. Animal studies evaluate toxicity. Clinical studies involve pharmacokinetic and pharmacodynamic comparisons as well as clinical immunogenicity assessments. The totality of the evidence from the biosimilar development program must prove no clinically meaningful differences exist from the reference product. Most major regulatory authorities such as the U.S. FDA and EMA in Europe have established clear guidelines for the approval of biosimilars.
Cost Savings from Biosimilars
By increasing competition in the biologics market, biosimilars can help lower healthcare costs significantly. Once exclusivity periods for reference biologics expire, biosimilars are eligible to enter the market at a discount to the reference product, usually 15-25% lower in price. Due to their large size and complexity, biologic drugs are typically much more expensive than traditional small molecule drugs. The cost savings realized from biosimilars are therefore substantial. For example, when the first biosimilar versions of Humira entered the European market in 2018 after patents expired, prices dropped 40-50%. This illustrates how biosimilars can improve access to critical treatments while reducing healthcare spending.
Get more insights on - Biosimilars
English
Arabic
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian